2016 American Transplant Congress
Elevated Lung Shunt Fraction as an Independent Predictor of Local Disease Progression and Metastasis in Hepatocellular Carcinoma.
Purpose: To establish a relationship between lung shunt fraction (LSF) and local disease progression as well as the development of metastatic disease.Materials and Methods: A…2016 American Transplant Congress
The Impact of Etiology of Liver Disease and Indication for Transplantation on Access to the Liver Transplant Waiting List in the United States.
Background: Only a small fraction of patients with end-stage liver disease (ESLD) is waitlisted for liver transplantation (LT).Methods: Retrospective cohort study of transplant-eligible ESLD patients…2016 American Transplant Congress
3D-FLM (First, Last, Max): A Novel Summative Measure of Hepatocellular Carcinoma (HCC) Tumor Burden Predicts HCC Recurrence After Liver Transplantation (LT).
1Univ. Colorado, Aurora; 2UCSF, San Francisco.
Risk of recurrent HCC post-LT depends on tumor aggressiveness, pre-LT HCC burden and treatment response while waiting for LT. Standard measures of pre-LT HCC burden…2016 American Transplant Congress
Long-Term Outcomes After Pediatric Liver Transplantation for Malignant Liver Tumors: Effects of Era and Age.
Background: Hepatoblastoma (HB), hepatocellular carcinoma (HCC), along with hemangioendothelioma, hemangiosarcoma, and angiosarcoma (HHA) are rare tumors in children that are treated with orthotopic liver transplantation…2016 American Transplant Congress
Transplantation for Hepatocellularcarcinoma Is There a Tumor Size Limit?
Background:The advent of tumor size based criteria (Milan and UCSF) for transplantation of Hepatocellular carcinomas (HCC) has facilitated access of tumor patients to transplantation. Recent…2016 American Transplant Congress
Predictors of Ultrasound Failure to Detect Hepatocellular Carcinoma in Cirrhotic Livers.
University of California, San Francisco, San Francisco, CA.
Background: Current guidelines recommend ultrasound (US) for hepatocellular carcinoma (HCC) surveillance in cirrhotic livers. However, certain patient and disease characteristics may pose a technical challenge…2016 American Transplant Congress
Use of Autotransfusion During Liver Transplantation for Hepatocellular Carcinoma Does Not Increase Recurrence.
Baylor University Medical Center, Dallas, TX.
IntroductionAutotransfusion (AT) is rarely used in liver transplantation of hepatocellular carcinoma (HCC) patients due to the fear of disease transmission. Leukocyte depleting filters (LDF) can…2016 American Transplant Congress
Pre-Transplant Loco-Regional Therapy for Hepatocellular Carcinoma and Post-Transplant Outcomes: A National Study.
1Saint Louis Univ, Saint Louis; 2East Carolina Univ, Greenville.
Currently most transplant centers use loco-regional therapy to bridge liver transplant (LT) candidates with hepatocellular carcinoma (HCC). However, limited data are available to support the…2016 American Transplant Congress
Intraoperative Blood Loss Is a Promoter of Early Tumor Recurrence in Liver Transplant Patients with High Risk Hepatocellular Carcinoma.
Background:Currently, there is an increasing body of evidence that risk of early hepatocellular carcinoma (HCC) relapse following liver transplantation (LT) may be promoted by mechanisms…2016 American Transplant Congress
Traditionally Unacceptable Organs Promote Liver Transplantation in Patients with Long Waiting Times in the Share 35 Era.
Hepatocellular carcinoma (HCC) remains the most commonly granted MELD exception (M/E). Share 35 has disadvantaged this population. We have developed a strategy to use traditionally…
- « Previous Page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- …
- 23
- Next Page »